An investigation into serotonergic and environmental interventions against depression in a simulated delayed reward paradigm
Abstract
The disruption of the serotonergic (5HT) system has been implicated in causing major depression and the standard view is that a lack of serotonin is to blame for the resulting symptoms. Consequently, pharmacological interventions aim to increase serotonin concentration in its target areas or stimulating excitatory 5HT receptors. A standard approach is to use serotonin reuptake inhibitors (SSRIs) which cause a higher accumulation of serotonin. Another approach is to stimulate excitatory serotonin receptors with psychedelic drugs. This paper compares these two approaches by first setting up a system level limbic system model of the relevant brain areas and then modelling a delayed reward paradigm which is known to be disrupted by a lack of 5HT. Central to our model is how serotonin changes the response characteristics of decision making neurons where low levels of 5HT allows small signals to pass through whereas high levels of 5HT create a barrier for smaller signals but amplifying larger ones. We show with both standard behavioural simulations and model checking that SSRIs perform significantly better against interventions with psychedelics. However, psychedelics might work better in other paradigms where a high level of exploration is beneficial to obtain rewards.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 0.24
- Field percentile
- 48th percentile
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A dual-receptor model of serotonergic psychedelics
Arthur Juliani, Veronica Chelu, … Adam Safron·bioRxiv·Apr 12, 2024
- Serotonin reuptake inhibition rapidly enhances affect-reward coupling and improves mood over time
Regan Mills, Anais Durand, … Liam Mason·bioRxiv·Jul 8, 2026
- Psilocybin rapidly, but not immediately, reverses reward learning deficits in a durable manner in an inflammatory rat model of depressive symptoms
Justyna K. Hinchcliffe, Christopher Webb Thomas, … Emma S. J. Robinson·bioRxiv·Jan 15, 2026
- Distinct Modulatory Effects on Affective Biases by Different Serotonergic Psychedelics and MDMA in Male Rats: Possible Implications for Antidepressant Effects
Justyna K. Hinchcliffe, Julia Bartlett, … Emma S. J. Robinson·bioRxiv·Apr 22, 2026
- Direct serotonin release in humans shapes decision computations within aversive environments
Michael Colwell, Hosana Tagomori, … Catherine J. Harmer·Nature CommunicationsPeer-reviewed·Aug 9, 2024
- Brain dynamics predictive of response to psilocybin for treatment-resistant depression
Jakub Vohryzek, Joana Cabral, … Morten L. Kringelbach·Brain CommunicationsPeer-reviewed·Jan 1, 2024